Oddity Tech Ltd. (NASDAQ: ODD) is set to release its quarterly earnings on November 19, 2025. Analysts predict an earnings per share (EPS) of $0.35 and revenue of around $145.47 million. Oddity, known for its brands Il Makiage and Spoiled Child, is expanding its portfolio with the launch of Methodiq, a telehealth platform for medical skincare.
Methodiq marks Oddity's entry into the medical-grade skincare market, competing with companies like Hims. The platform offers 28 new products, including creams and supplements, targeting skin conditions such as acne and eczema. Prices range from $29 to $59, making these products accessible to a wide audience. This strategic move taps into a market expected to reach $113 billion this year.
The launch of Methodiq is a result of four years of development, integrating Oddity's investments in biotechnology and AI-based computational imaging. This innovation allows for online diagnosis and personalized treatments, eliminating the need for traditional doctor visits. The platform's focus on dermatology treatments highlights Oddity's commitment to leveraging technology for accessible healthcare.
Financially, Oddity has a price-to-earnings (P/E) ratio of 18.89, reflecting the market's valuation of its earnings. The price-to-sales ratio is 2.76, indicating investor willingness to pay per dollar of sales. The enterprise value to sales ratio is 1.92, showing the company's total valuation relative to its sales.
Oddity's financial health is further supported by a low debt-to-equity ratio of 0.065, indicating conservative debt use. The current ratio of 6.32 suggests strong liquidity, ensuring the company can cover short-term liabilities. With an earnings yield of 5.29%, Oddity demonstrates its ability to generate earnings from each dollar invested.
